{"id":1291,"date":"2021-05-21T11:48:00","date_gmt":"2021-05-21T09:48:00","guid":{"rendered":"https:\/\/lensounds.com\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/"},"modified":"2021-05-21T11:48:00","modified_gmt":"2021-05-21T09:48:00","slug":"pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/","title":{"rendered":"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer"},"content":{"rendered":"

Abstract<\/h2>\n

This early Phase I pilot open-label feasibility study evaluates the safety, tolerability, radiation dosimetry, and imaging properties of 89<\/sup>Zr-labeled girentuximab, a radiopharmaceutical targeting the carbonic anhydrase IX (CAIX) antigen, for PET\/CT imaging in patients with non-muscle invasive bladder cancer (NMIBC). The study enrolled 6 patients with NMIBC to assess the diagnostic potential of this novel imaging agent. 89<\/sup>Zr-girentuximab enables precise visualization of CAIX-expressing tumor cells, offering valuable insights for patient selection and treatment planning in targeted alpha therapy approaches. This monocentric, prospective study was conducted at Institut de Canc\u00e9rologie de l’Ouest (ICO) in collaboration with Atonco, contributing to the development of theranostic strategies combining diagnostic imaging with therapeutic applications using the anti-CAIX antibody girentuximab.<\/p>\n

Publication Information<\/h2>\n

Source:<\/strong> ClinicalTrials.gov<\/p>\n

Trial Registration Date:<\/strong> May 21, 2021<\/p>\n

Study Completion Date:<\/strong> September 26, 2022<\/p>\n

Trial ID:<\/strong> NCT04897763<\/p>\n

Study Status:<\/strong> COMPLETED<\/p>\n

ClinicalTrials.gov Link:<\/strong> https:\/\/clinicaltrials.gov\/study\/NCT04897763<\/a><\/p>\n

Authors<\/h2>\n

Sponsor:<\/strong> Institut de Canc\u00e9rologie de l’Ouest (ICO)<\/p>\n

Collaborator:<\/strong> Atonco<\/p>\n

Principal Investigator:<\/strong> Caroline Rousseau, MD, PhD<\/p>\n

Institutional Affiliation:<\/strong> Institut de Canc\u00e9rologie de l’Ouest, Saint-Herblain (44805), France<\/p>\n

Phase:<\/strong> Early Phase I (Diagnostic)<\/p>\n

Actual Enrollment:<\/strong> 6 patients<\/p>\n

Study Timeline:<\/strong> October 1, 2021 \u2013 September 26, 2022<\/p>\n

Study Design:<\/strong> Monocentric, open-label, prospective, single-arm<\/p>\n","protected":false},"excerpt":{"rendered":"

ClinicalTrials.gov ID: NCT04897763
\n Sponsor: Institut de Canc\u00e9rologie de l’Ouest (ICO)
\n Collaborator: Atonco
\n ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT04897763<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[50],"class_list":["post-1291","science","type-science","status-publish","hentry","science_category-ato-101-publications"],"yoast_head":"\nPERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco\" \/>\n<meta property=\"og:description\" content=\"ClinicalTrials.gov ID: NCT04897763 Sponsor: Institut de Canc\u00e9rologie de l'Ouest (ICO) Collaborator: Atonco ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT04897763\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\\\/\",\"name\":\"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2021-05-21T09:48:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/","og_locale":"en_US","og_type":"article","og_title":"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco","og_description":"ClinicalTrials.gov ID: NCT04897763 Sponsor: Institut de Canc\u00e9rologie de l'Ouest (ICO) Collaborator: Atonco ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT04897763","og_url":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/","og_site_name":"Atonco","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/","url":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/","name":"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2021-05-21T09:48:00+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"PERTINENCE: A Pilot Study to Assess Safety, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled Girentuximab in Non-Muscle Invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/1291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1291"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=1291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}